The Association Between Time of Lipid-Lowering Therapy Initiation and Acute Clinical Presentation Among Patients Admitted With Coronary Artery Disease, and Its Effect on Future Cardiovascular Events: An Australian Observational Study

被引:0
|
作者
Eccleston, David [1 ,2 ]
Chowdhury, Enayet K. [1 ]
Wang, Alex [3 ]
Yeh, Eric J. [4 ]
Rezkalla, Nevine [3 ]
Kathe, Niranjan [4 ]
Williamson, Anna E. [1 ]
Schwarz, Nisha [1 ]
机构
[1] Advara HeartCare, Brisbane, Qld, Australia
[2] Univ Melbourne, Parkville, Vic, Australia
[3] Amgen Inc, Sydney, NSW, Australia
[4] Amgen Inc, Thousand Oaks, CA USA
来源
HEART LUNG AND CIRCULATION | 2025年 / 34卷 / 02期
关键词
Lipid-lowering therapy; Coronary artery disease; Percutaneous coronary intervention; Acute coronary syndrome; ACUTE MYOCARDIAL-INFARCTION; STATIN THERAPY; LDL-C; ADMISSION; RISK; MORTALITY; OUTCOMES;
D O I
10.1016/j.hlc.2024.08.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Lipid-lowering therapy (LLT) is established as a key element in management of patients with coronary artery disease. However, the effect of time of initiation of LLT on outcomes is unclear. Method The study compared outcomes of 5,433 patients from Advara HeartCare's Percutaneous Coronary Intervention (PCI) Registry on the basis of timing of LLT initiation classified as pre- or post-PCI admission. The prevalence of acute coronary syndrome (ACS) as the indication for PCI was compared in groups. In patients who underwent PCI for ACS, the incidence of short- (<30 days) and long-term (>30 days after admission) clinical events (composite of myocardial infarction, cerebrovascular disease, coronary revascularisation, all-cause readmission, and mortality) and first non-fatal cardiovascular events were compared in groups. Results At the time of hospitalisation for PCI, 3,982 (73.7%) were on LLT (PRE-LLT), and 1,418 (26.2%) initiated LLT after admission (POST-LLT). Patients on PRE-LLT were significantly less likely to experience ACS before admission for PCI than were those commencing LLT after discharge (PRE-LLT 32.3% vs POST-LLT 56.9%; p<0.001), even after matching for baseline risk factors. Among these patients with ACS, patients on PRELLT were older than those on POST-LLT (mean 69.5 +/- 9.5 vs 65.0 +/- 10.0 years; p<0.001), and had a higher prevalence of cardiovascular risk factors including diabetes (31.5% vs 9.6%; p<0.001), hypertension (79.7% vs 51.7%; p<0.001), and renal failure (7.6% vs 2.0%; p<0.001). No difference was observed between groups in the risk of short- or long-term (median 2.0 years; interquartile range 1.0-3.0) post-PCI cardiovascular (hazard ratio [HR] 1.08; 0.83-1.40; p=0.55) or overall clinical events (HR 1.11; 0.93-1.32; p=0.26). Conclusions In patients with coronary artery disease, the risk of ACS is reduced by early initiation of LLT before revascularisation is required. Long-term outcomes of patients at high risk prescribed LLT before admission for ACS PCI may not differ from those of patients at lower risk commencing LLT after PCI for ACS.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 8 条
  • [1] Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA)
    Flueckiger, Peter
    Qureshi, Waqas
    Michos, Erin D.
    Blaha, Michael
    Burke, Gregory
    Sandfort, Veit
    Herrington, David
    Yeboah, Joseph
    CLINICAL CARDIOLOGY, 2017, 40 (03) : 163 - 169
  • [2] Relation Between Blood Pressure Lowering Therapy and Adverse Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease: The Hij-create Sub-study
    Ogawa, Hiroshi
    Minami, Yuichiro
    Yamaguchi, Jun-ichi
    Koyagani, Ryo
    Kawada-Watanabe, Erisa
    Takagi, Atsushi
    Hagiwara, Nobuhisa
    CIRCULATION, 2012, 126 (21)
  • [3] ASSOCIATION BETWEEN DAILY GLUCOSE FLUCTUATION AND CORONARY PLAQUE PROPERTIES IN PATIENTS RECEIVING LIPID-LOWERING THERAPY ASSESSED BY CONTINUOUS GLUCOSE MONITORING AND OPTICAL COHERENCE TOMOGRAPHY: A PROSPECTIVE OBSERVATIONAL STUDY
    Kuroda, Masaru
    Shinke, Toshro
    Sakaguchi, Kazuhiko
    Otake, Hiromasa
    Takaya, Tomofumi
    Hirota, Yushi
    Osue, Tsuyoshi
    Kinutani, Hiroto
    Konishi, Akihide
    Takahashi, Hachidai
    Terashita, Daisuke
    Uzu, Kenzo
    Shinkura, Yuto
    Tahara, Natsuko
    Kuroda, Koji
    Kashiwagi, Daiji
    Nagasawa, Keisuke
    Hirata, Ken-ichi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1851 - A1851
  • [4] Relation between Blood Pressure Lowering Therapy and Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease and Chronic Kidney Disease -The HIJ-CREATE Sub-study
    Ogawa, Hiroshi
    Kawada-Watanabe, Erisa
    Okayama, Dai
    Arashi, Hiroyuki
    Yamaguchi, Jun-ichi
    Takagi, Atsushi
    Hagiwara, Nobuhisa
    CIRCULATION, 2013, 128 (22)
  • [5] Differences in the usefulness of aggressive lipid-lowering therapy among single-vessel and multi-vessel coronary artery disease patients: HIJ-PROPER sub-study
    Ogido, M.
    Nomura, H.
    Nakawaza, M.
    Kawada-Watanabe, E.
    Sekiguchi, H.
    Arashi, H.
    Yamaguchi, J.
    Ogawa, H.
    Hagiwara, N.
    EUROPEAN HEART JOURNAL, 2019, 40 : 431 - 431
  • [6] Relation between blood pressure lowering therapy and cardiovascular events and mortality in hypertensive patients with coronary artery disease and type 2 diabetes: the HIJ-CREATE sub-study
    Ogawa, H.
    Koyanagi, R.
    Kawada-Watanabe, E.
    Yamaguchi, J.
    Takagi, A.
    Hagiwara, N.
    EUROPEAN HEART JOURNAL, 2012, 33 : 657 - 657
  • [7] Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study
    Kamishima, K.
    Ogawa, H.
    Jujo, K.
    Yamaguchi, J.
    Hagiwara, N.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 149 : 69 - 77
  • [8] Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL- CAD Study
    Kamiya, Kiwamu
    Takei, Makoto
    Nagai, Toshiyuki
    Miyoshi, Toru
    Ito, Hiroshi
    Fukumoto, Yoshihiro
    Obara, Hitoshi
    Kakuma, Tatsuyuki
    Sakuma, Ichiro
    Daida, Hiroyuki
    Iimuro, Satoshi
    Shimokawa, Hiroaki
    Kimura, Takeshi
    Nagai, Ryozo
    Anzai, Toshihisa
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (01) : 61 - 80